Saldanha A C, Romero G A, Merchan-Hamann E, Magalhães A V, Macedo V de O
Núcleo de Medicina Tropical e Nutrição, Universidade de Brasilia, Brasil.
Rev Soc Bras Med Trop. 1999 Jul-Aug;32(4):383-7. doi: 10.1590/s0037-86821999000400008.
Efficacy and safety of meglumine antimoniate and sodium stibogluconate BP 88R were compared in cutaneous leishmaniasis treatment in Corte de Pedra, Bahia, an endemic area of leishmaniasis due to Leishmania (Viannia) braziliensis. An open trial was developed with one hundred twenty seven patients who were diagnosed based on clinical criteria and Montenegro's skin test. Fifty eight patients were treated with meglumine antimoniate and 69 received sodium stibogluconate. Both groups received 20 mg/Sbv/kg/day for 20 days. Patients were followed every ten days during treatment and every month thereafter for three months. Sixty two percent patients cured with meglumine antimoniate and 55% cured with sodium stibogluconate (p = 0.42). Headache was more frequent during the first half of treatment in patients receiving sodium stibogluconate (p = 0.026). During the second half, patients treated with sodium stibogluconate showed a greater frequency of myalgia/arthralgia (p = 0.004) and abdominal pain/anorexia (p = 0.004). Three patients treated with sodium stibogluconate had severe side effects.
在巴伊亚州佩德拉堡（利什曼病的一个流行地区，该病由巴西利什曼原虫（维安尼亚利什曼原虫）引起）的皮肤利什曼病治疗中，比较了葡甲胺锑酸盐和BP 88R葡萄糖酸锑钠的疗效和安全性。开展了一项开放性试验，纳入了127例根据临床标准和蒙氏皮肤试验确诊的患者。58例患者接受葡甲胺锑酸盐治疗，69例接受葡萄糖酸锑钠治疗。两组均接受20mg/Sbv/kg/天的治疗，持续20天。治疗期间每10天对患者进行随访，此后每月随访一次，共随访三个月。接受葡甲胺锑酸盐治疗的患者治愈率为62%，接受葡萄糖酸锑钠治疗的患者治愈率为55%（p = 0.42）。接受葡萄糖酸锑钠治疗的患者在治疗前半期头痛更为频繁（p = 0.026）。在治疗后半期，接受葡萄糖酸锑钠治疗的患者肌痛/关节痛（p = 0.004）和腹痛/厌食（p = 0.004）的发生率更高。3例接受葡萄糖酸锑钠治疗的患者出现严重副作用。
